News for Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics (NRIX) is set to take part in an upcoming conference organized by Oppenheimer on June 23-24. This event presents a valuable opportunity for t

NuCana (NRIX) is set to take part in an upcoming conference organized by Oppenheimer on June 23-24. This event presents a valuable opportunity for the company t

Nurix Therapeutics (NRIX) granted inducement awards to 17 new employees on June 10, 2025. The inducement includes stock options for 97,400 shares with a

**media[654537]**

Nurix Therapeutics (NRIX) stock falls as the company posts new early-stage trial data for its lead asset bexobrutideg (NX-5948) in B-cell malignancies. Read more here.

Air India Boeing jet crashes shortly after takeoff. Nvidia and Samsung to take minority stakes in robotics startup Skild AI - report. Chime Financial prices IPO at $27, above expected price.

Nurix Therapeutics (NRIX) to discuss new data from Phase 1 trial of bexobrutideg (NX-5948) in a webcast on June 12, 2025. Data includes efficacy in relapsed

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 m

Nurix Therapeutics (NRIX) has announced that Sanofi is moving forward with the exclusive licensing of Nurix's STAT6 program, which includes the promising candid

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells

**media[638992]**

**media[628728]**

SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( NRIX), a clinical-stage biopharmaceutical company focused on the discovery, develop

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BR

On Wednesday, April 23, 2025, Cathie Wood of Ark Invest purchased more stock of AMD and Nvidia amid looming US chip curbs against China.

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025

**media[597931]**

Nurix Therapeutics (NRIX) granted inducement awards to 16 new employees as part of their 2024 Equity Inducement Plan. The awards comprise stock options

**media[592903]**